The purpose of this study to see if the drug ruxolitinib with the drugs tacrolimus and methotrexate given before and following a peripheral blood stem cell transplant will prevent graft-versus-host disease (GVHD), a serious complication of a stem cell transplant, better than the drugs post-transplant cyclophosphamide, tacrolimus, and mycophenolate mofetil.
COM_RESEARCHSTUDIES_DETAIL_HEADER_BASIC_CONTACT_4
North Carolina (Statewide)
Anson Snow
LCCC - Clinical Trials
Clinical or Medical
Interventional
Cancer (Leukemia, Lymphoma)
Transplant
24-2867